Overview

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Status:
COMPLETED
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb